Biosana enters exclusive global licensing agreement with Alvotech for co-development of a Proposed Biosimilar (AVT23) to Xolair® (Omalizumab)
Leiden, February 2, 2022 – BiosanaPharma, a Gold Nest Capital portfolio company, has entered into a global licensing agreement with Alvotech to co-develop BP001, a biosimilar of Xolair (omalizumab). Under this agreement, BiosanaPharma and Alvotech…
Allecra Therapeutics and Advanz Pharma Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe
SAINT-LOUIS, France and WEIL AM RHEIN, Germany and LONDON, UK, January 13, 2022 – ADVANZ PHARMA Corp. Limited (“ADVANZ PHARMA”), a specialty pharmaceutical company with a strategic focus on hospital medicines in Europe, and Allecra…
BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies
MAINZ, Germany and CAMBRIDGE, UK, January 10, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Crescendo Biologics Ltd (“Crescendo”), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announced that they have entered…
Insights on the Biochips Global Market to 2026
Dublin, December 20, 2021 – The global biochips market exhibited strong growth during 2015-2020. Looking forward, the market is expected to grow at a CAGR of around 15% during 2021-2026. Keeping in mind the uncertainties…
Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round
HAMBURG, GERMANY / July 29, 2021 – Topas Therapeutics (Topas), a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of autoimmune diseases, today announced that the Company has successfully…
MIMETAS wins Deshima award for Dutch-Japanese business relations
Leiden & Tokyo, June 7, 2021 – MIMETAS has been awarded the “Deshima Business Award” in the category “newly established” by the Netherlands Chamber of Commerce in Japan (NCCJ), and the Embassy of the Kingdom…
MIMETAS and Roche Enter into a Collaboration to Develop Human Disease Models for Drug Development
Leiden, July 6, 2021 – MIMETAS, a leader in organ-on-chip-based disease models and technology, and Roche, a world-leading pharmaceutical company, announced today that they have entered into a collaboration to develop human disease models to…
Nature Communication publishes application of switchSENSE technology in multivalent antibody development
Leiden, July 18, 2021 – Today, Andreas Plückthun’s group at the University of Zurich publishes on Nature Communication with the help of switchSENSE technology. The paper shows that an engineered anti-Her2 tetravalent antibody construct that…
UK eases the way to market for biosimilars
Today, UK’s Medicines & Healthcare products Regulatory Agency (MHRA) published the final guidance on the licensing of biosimilar products, lowering the barrier for biosimilar drug to enter the market. Today’s final version follows draft guidelines…
Conformation analysis realized by switchSENSE published in Proceedings of National Academy of Science
La Jolla, LA, March 30, 2021 – Litao Sun, et al, at Scripps Research used the switchSENSE® technology in their paper to analyze the different conformations of the wild-type and mutant versions of the alanyl-tRNA…